Across TCGA pan-cancer cohorts, UBALD2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of UBALD2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where UBALD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types UBALD2 is over-expressed in tumor.
CCRCC and LSCC are the cancer types where UBALD2 tumor–normal differential expression is most reproducible.